TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients who experience CRS
Endpoint domain: Adverse events/effects
Primary endpoint: Caregiver Burden
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Emotional Health Strain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ULS-8 Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in presence and severity of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceptions of daily life stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Viable pregnancy beyond 10 weeks' gestation
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with completely healed bone graft surgical site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful vascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of STI-6129
Endpoint domain: Adverse events/effects
Primary endpoint: Change in gait post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HRV via RMSSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF levels of fetuin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hsCRP evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved radiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operation complication
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (complete and partial response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in plasma biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in cerebral amyloid pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of change in Tau PET measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total annualised bleeding rate (tABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-level Sensitivity of Vidoflufolastat (18F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Region-level Specificity of Vidoflufolastat (18F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with controlled disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of undesirable events associated with opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Circadian phase of melatonin rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of daily caloric intake in the biological evening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of UltraSight AI guidance software
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in GDMT medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary peptide differential expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute kidney injury recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of lymphoma patients that require treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of lymphoma patients under active surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month radial artery graft failure
Endpoint domain: Mortality/survival
Primary endpoint: 7-day radial artery graft failure
Endpoint domain: Mortality/survival
Primary endpoint: Identification of mitochondrial DNA variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnosis of gastrointestinal mucosal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Body Composition and Anthropometric Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunity and Systemic-Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: World Health Organization Disability Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: World Health Organization Quality of Life BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the effect curve (AUEC) of serum C-telopeptide of Type-1 collagen (sCTX) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in amount of produce purchased or accessed
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Change in Produce Intake
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Renal affection degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of Sweat Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of positive urine culture for which antibiotic therapy was prescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum tolerated dose (MTD) of ES009
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Optimal biological dose (OBD) of ES009
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Child social communication skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: focal seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants Experiencing Treatment Related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: HbA1c after Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c after Cycle 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life (QOL) at day 20
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity of leucocyte subpopulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Specificity of leucocyte subpopulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet indices with early clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in lung diffusing capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in chest CT findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical activity time and levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe aGVDH free survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax of unconjugated and total dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of unconjugated and total dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Treatment Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ADHD Symptoms and Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Gait Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes to mucosal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes to mucosal health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Genomic changes associated with skin cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Airway invasion outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in skin health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Volumetric buccal soft tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriatic Arthritis Disease Activity Score (DAPSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand grip strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hand fine grip strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Completion of cognitive interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of saliva biomarker quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of oral health behaviors and clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of ATX-559
Endpoint domain: Adverse events/effects
Primary endpoint: Hazard of failure of total elbow replacement
Endpoint domain: Mortality/survival
Primary endpoint: amyloid PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean mMRC Dyspnea Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in percentage of participants retained
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who adhere to diet measured by 24 hour dietary recall
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients who adhere to medications measured by self report
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Repayment behaviour - time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Repayment behaviour - percentage revenue
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain in low back area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous congestion (VExUS) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Profile Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subdural intracranial pressure (sICP) mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Problem Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of neurological deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: prevalence of fibrosis, edema and altered T1 mapping values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of patients with DSA among all the enrolled patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological diagnosis of rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perioperative RBC transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rotational head acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric neck strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Ferritin (SF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Event rate of GI side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Eyes With Acceptable Lens Fitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with grade 3 adverse events related to tremelimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal tremelimumab dose that produces grade 3 adverse events in less than 2 participants
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety Depression Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: changes in peak intensity (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage increase in the perfusion area (%) of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nutrition Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Rate of Human Immunodeficiency Virus (HIV) testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Rate of pre-exposure prophylaxis (PrEP) uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the amount of use of HIV care services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference of pain severity from baseline to 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of pain severity from baseline to 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of Adolescent Relationships and Harassment and Abuse - Victimization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measure of Adolescent Relationships and Harassment and Abuse - Perpetration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Monitoring the future alcohol use intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance of cardiac arrhythmias classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance of step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of the open eruption technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort and Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: C-telopeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of successful non-operative management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful pathologic complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with abnormalities of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with major structural defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence for Text Messages
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Cooking Sessions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Red blood cell transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of IL13Rα2 CAR-T
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy - sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy - specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoxemic Respiratory Failure and Pulmonary Hypertension (HRF/PH) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of blemishes, lines, and wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with recurrent stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Major Adverse Clinical Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Persistent Cardiac Abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional Assessment: Number of Participants Reporting Symptoms of Chest Pain, Dyspnea, Palpitations, and Syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: high grade serous ovarian cancer incidence
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SARS-CoV-2 neutralizing antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average number of passes needed to place the catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants who Experience a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Experience a Dose Interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Experience a Dose Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: protein-bound toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internet Addiction Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour pH measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of completeness of all aspects of the study: Blood samples for pharmacogenetics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diabetes Technology Utilization Score (DTUS) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of anti-Delta-positive subjects connected to tertiary services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection rate of HDV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects evaluated for therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood Oxygen Level Dependent (BOLD) signal in the hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hippocampal (Hpc) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Threat reactivity measured via skin conductance response (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to accrue 20 patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 3-year local recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Change in Quality of life as measured by MD Anderson Dysphagia Inventory (MDADI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of life as measured by the Sydney Swallow Questionnaire (SSQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device Survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Serum asprosin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV-DNA test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: B scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consolidation Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving IGA 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Night wetting frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Inotrope Exposure Score (TIES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vasoactive-Inotropic Score (VIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease activity measured as DAS28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the NNC0519-0130 plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes